Newly-created committee will work to help improve Florida's medical marijuana policies
TORONTO, June 14, 2019 /CNW/ - Trulieve Cannabis Corp. ("Trulieve" or the "Company") (CSE: TRUL) CEO Kim Rivers has been appointed to the newly-established Medical Marijuana Advisory Committee for the State of Florida. This committee will collaborate with the Florida Department of Agriculture and Consumer Services to help enhance the medical marijuana policies of the state.
"Every day, our Trulieve team helps to bring relief to thousands of people suffering from a range of debilitating ailments and improve their quality of life," said Kim Rivers, CEO of Trulieve. "I am honored to be a part of this important initiative led by Commissioner Nikki Fried to further develop patient access and advance policies related to medical marijuana in Florida."
The Florida Department of Agriculture and Consumer Services has stated that the committee will convene telephonically and in-person bi-monthly to work through ways to expand patient access, increase innovation and technology in the industry, and make recommendations to the Legislature and the Department of Health's Office of Medical Marijuana Use to improve Florida's medical marijuana policies and programs. The 18-member committee is comprised of representatives with a diverse range of backgrounds, including medical marijuana production and sales, science and medicine, law, medical marijuana patients, cannabis activists, and public affairs.
Trulieve is a vertically integrated "seed to sale" company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL.
This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
To learn more about Trulieve, visit www.Trulieve.com.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
SOURCE Trulieve Cannabis Corp.
For further information: Lynn Ricci, Director, Investor Relations, 850-270-5691, IR@trulieve.com